Amgen To Present the New Data from Pivotal P-III (NAVIGATOR) and P-IIb (PATHWAY) Trials of Tezspire at the 2022 AAAAI Annual Meeting
Shots:
- The results from a pooled post-hoc analysis of the pivotal P-III (NAVIGATOR) and P-IIb (PATHWAY) trials of Tezspire + SoC, showed improvements and consistent efficacy with a 71% (≥300 cells per microliter), 48% (<300 cells per microliter) and 48% (<150 cells per microliter) reductions in the AAER@52 wks. vs. PBO + SoC
- Tezspire reduced the AAER by 63% (winter), 46% (spring), 62% (summer) and 54% (autumn) which was lower than PBO group
- Tezspire is approved in the US for the treatment of severe asthma and is under regulatory review in the EU, Japan, and several other countries
Ref: Amgen | Image: Adweek
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
